{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:01:24Z","timestamp":1790312484631,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangdong Provincial Clinical Research Center for Breast Diseases","award":["2023B110005"],"award-info":[{"award-number":["2023B110005"]}]},{"name":"National Science and Technology Major Project for the Prevention and Treatment of Cancer, Cardiovascular, Respiratory, and Metabolic Diseases","award":["2024ZD0519800; 2024ZD0519805"],"award-info":[{"award-number":["2024ZD0519800; 2024ZD0519805"]}]},{"name":"National Natural Science Foundation of China","award":["82203141"],"award-info":[{"award-number":["82203141"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["82271793; 82573593"],"award-info":[{"award-number":["82271793; 82573593"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China","award":["82573479"],"award-info":[{"award-number":["82573479"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Guangzhou Science and Technology Plan Project","award":["SL2023A03J01150"],"award-info":[{"award-number":["SL2023A03J01150"]}]},{"name":"Guangzhou Science and Technology Plan Project","award":["2025A03J4194"],"award-info":[{"award-number":["2025A03J4194"]}]},{"name":"Guangzhou Science and Technology Plan Project","award":["2024A03J1195"],"award-info":[{"award-number":["2024A03J1195"]}]},{"name":"Sun Yat-sen Memorial Hospital Clinical Research Cultivation Program","award":["SYS-Q-202101"],"award-info":[{"award-number":["SYS-Q-202101"]}]},{"name":"Sun Yat-sen Memorial Hospital Clinical Research 5010 Program","award":["SYS-5010-202308"],"award-info":[{"award-number":["SYS-5010-202308"]}]},{"name":"Sun Yat-sen Memorial Hospital Clinical Research 5010 Program","award":["SYS-5010-202409"],"award-info":[{"award-number":["SYS-5010-202409"]}]},{"name":"Sun Yat-sen University Clinical Research 5010 Program","award":["81000-13130007"],"award-info":[{"award-number":["81000-13130007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10549-026-08070-9","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T06:37:20Z","timestamp":1788935840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring trop-2-directed ADCs monotherapy and combination therapy in pretreated mTNBC: a real-world study"],"prefix":"10.1007","volume":"219","author":[{"given":"Jingze","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxiaoxiao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhu","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"8070_CR1","doi-asserted-by":"crossref","unstructured":"Anders CK, Zagar TM, Carey LA (2013) The management of early-stage and metastatic triple-negative breast cancer: a review. Hematol. Oncol. Clin. North Am. 27;737\u2013749","DOI":"10.1016\/j.hoc.2013.05.003"},{"key":"8070_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4137\/BCBCR.S32783","volume":"10","author":"SB Zeichner","year":"2016","unstructured":"Zeichner SB, Terawaki H, Gogineni K (2016) A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer Basic Clin Res 10:25\u201336","journal-title":"Breast Cancer Basic Clin Res"},{"key":"8070_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/annonc\/mdw544","volume":"28","author":"F Cardoso","year":"2017","unstructured":"Cardoso F et al (2017) 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol Off J Eur Soc Med Oncol 28:16\u201333","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"8070_CR4","doi-asserted-by":"publisher","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","volume":"18","author":"WJ Gradishar","year":"2020","unstructured":"Gradishar WJ et al (2020) Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN 18:452\u2013478","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"8070_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10549-010-0824-0","volume":"121","author":"EA Perez","year":"2010","unstructured":"Perez EA, Patel T, Moreno-Aspitia A (2010) Efficacy of ixabepilone in ER\/PR\/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 121:261\u2013271","journal-title":"Breast Cancer Res Treat"},{"key":"8070_CR6","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s10549-012-2008-6","volume":"133","author":"A Brufsky","year":"2012","unstructured":"Brufsky A et al (2012) Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 133:1067\u20131075","journal-title":"Breast Cancer Res Treat"},{"key":"8070_CR7","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/annonc\/mdw203","volume":"27","author":"X Pivot","year":"2016","unstructured":"Pivot X et al (2016) Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol Off J Eur Soc Med Oncol 27:1525\u20131531","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"8070_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4143\/crt.2017.562","volume":"51","author":"IH Park","year":"2019","unstructured":"Park IH et al (2019) Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: PROCEED trial (KCSG BR 11 \u2013 01). Cancer Res Treat 51:43\u201352","journal-title":"Cancer Res Treat"},{"key":"8070_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP et al (2021) Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol 22:499\u2013511","journal-title":"Lancet Oncol"},{"key":"8070_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1200\/JCO.2010.31.6679","volume":"29","author":"SJ Isakoff","year":"2011","unstructured":"Isakoff SJ, Baselga J (2011) Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 29:351\u2013354","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"8070_CR11","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:1529\u20131541","journal-title":"N Engl J Med"},{"key":"8070_CR12","first-page":"621","volume":"16","author":"X Gao","year":"2024","unstructured":"Gao X, Bu T, Wang W, Xu Y (2024) Comparative analysis and future prospects of human epidermal growth factor receptor 2 (HER2) and trophoblast cell-surface antigen 2 (trop-2) targeted antibody-drug conjugates in breast cancer treatment. Breast Cancer Dove Med Press 16:621\u2013630","journal-title":"Breast Cancer Dove Med Press"},{"key":"8070_CR13","unstructured":"Sacituzumab govitecan vs chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/38864297\/"},{"key":"8070_CR14","unstructured":"Results from the randomized KEYNOTE- 355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/39266535\/"},{"key":"8070_CR15","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/jnci\/djae129","volume":"116","author":"R Dent","year":"2024","unstructured":"Dent R et al (2024) Neoadjuvant pembrolizumab plus chemotherapy\/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study. J Natl Cancer Inst 116:1654\u20131663","journal-title":"J Natl Cancer Inst"},{"key":"8070_CR16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/jama.2024.23560","volume":"333","author":"L Chen","year":"2025","unstructured":"Chen L et al (2025) Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer: the CamRelief randomized clinical trial. JAMA 333:673\u2013681","journal-title":"JAMA"},{"key":"8070_CR17","doi-asserted-by":"crossref","unstructured":"Schmid P et al (2024) 181O interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: a phase ib\/II study of multiple treatment (tx) combinations in pts with locally advanced\/metastatic BC (LA\/mBC). ESMO Open 9","DOI":"10.1016\/j.esmoop.2024.103203"},{"key":"8070_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.21037\/tbcr-25-32","volume":"6","author":"L Bian","year":"2025","unstructured":"Bian L, Zhang S, Li M, Yang J, Yin Y (2025) Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04. Transl. Breast Cancer Res J Focus Transl Res Breast Cancer 6:29","journal-title":"Breast Cancer Res J Focus Transl Res Breast Cancer"},{"key":"8070_CR19","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/s41591-025-03734-3","volume":"31","author":"M Gion","year":"2025","unstructured":"Gion M et al (2025) Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial. Nat Med 31:2746\u20132754","journal-title":"Nat Med"},{"key":"8070_CR20","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J et al (2022) Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nat Commun 13:3011","journal-title":"Nat Commun"},{"key":"8070_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10549-024-07412-9","volume":"208","author":"K Kalinsky","year":"2024","unstructured":"Kalinsky K et al (2024) Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Res Treat 208:203\u2013214","journal-title":"Breast Cancer Res Treat"},{"key":"8070_CR22","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.7150\/ijbs.70583","volume":"18","author":"Q Liu","year":"2022","unstructured":"Liu Q et al (2022) TOP1 inhibition induces bifurcated JNK\/MYC signaling that dictates cancer cell sensitivity. Int J Biol Sci 18:4203\u20134218","journal-title":"Int J Biol Sci"},{"key":"8070_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10549-013-2793-6","volume":"143","author":"M Fan","year":"2014","unstructured":"Fan M et al (2014) Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat 143:141\u2013151","journal-title":"Breast Cancer Res Treat"},{"key":"8070_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1158\/1078-0432.CCR-21-1810","volume":"28","author":"M S\u00e1nchez-Guix\u00e9","year":"2022","unstructured":"S\u00e1nchez-Guix\u00e9 M et al (2022) High FGFR1\u20134 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer. Clin Cancer Res 28:137\u2013149","journal-title":"Clin Cancer Res"},{"key":"8070_CR25","doi-asserted-by":"publisher","first-page":"9170","DOI":"10.1038\/s41598-017-08971-2","volume":"7","author":"P Mukherjee","year":"2017","unstructured":"Mukherjee P et al (2017) Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells. Sci Rep 7:9170","journal-title":"Sci Rep"},{"key":"8070_CR26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/bab.1790","volume":"66","author":"M Marzbany","year":"2019","unstructured":"Marzbany M, Bishayee A, Rasekhian M (2019) Increased expression of ZNF703 in breast cancer tissue: an opportunity for RNAi\u2013NSAID combinatorial therapy. Biotechnol Appl Biochem 66:808\u2013814","journal-title":"Biotechnol Appl Biochem"},{"key":"8070_CR27","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","volume":"35","author":"LM Spring","year":"2024","unstructured":"Spring LM et al (2024) Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial. Ann Oncol Off J Eur Soc Med Oncol 35:293\u2013301","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"8070_CR28","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-20-4726","volume":"27","author":"SM Tolaney","year":"2021","unstructured":"Tolaney SM et al (2021) Eribulin plus pembrolizumab in patients with metastatic triple-negative breast cancer (ENHANCE 1): a phase ib\/II study. Clin. Cancer Res Off J Am Assoc Cancer Res 27:3061\u20133068","journal-title":"Cancer Res Off J Am Assoc Cancer Res"},{"key":"8070_CR29","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1078-0432.CCR-19-2179","volume":"26","author":"Q Li","year":"2020","unstructured":"Li Q et al (2020) Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clin Cancer Res Off J Am Assoc Cancer Res 26:1712\u20131724","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"8070_CR30","doi-asserted-by":"publisher","first-page":"eadn0904","DOI":"10.1126\/scitranslmed.adn0904","volume":"16","author":"Z Lu","year":"2024","unstructured":"Lu Z et al (2024) Modified C-type natriuretic peptide normalizes tumor vasculature, reinvigorates antitumor immunity, and improves solid tumor therapies. Sci Transl Med 16:eadn0904","journal-title":"Sci Transl Med"},{"key":"8070_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12951-025-03170-y","volume":"23","author":"Y Liu","year":"2025","unstructured":"Liu Y et al (2025) Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity. J Nanobiotechnol 23:194","journal-title":"J Nanobiotechnol"},{"key":"8070_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D et al (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15:325\u2013340","journal-title":"Nat Rev Clin Oncol"},{"key":"8070_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1001\/jamaoncol.2023.5424","volume":"10","author":"BD Lehmann","year":"2024","unstructured":"Lehmann BD et al (2024) Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: the TBCRC 043 phase 2 randomized clinical trial. JAMA Oncol 10:193\u2013201","journal-title":"JAMA Oncol"},{"key":"8070_CR34","first-page":"P1","volume":"31","author":"J Liu","year":"2025","unstructured":"Liu J et al (2025) Abstract P1-07-28: Real-World Study on Efficacy and Safety of SG Alone and Combined with Immunotherapy in Metastatic Triple Negative Breast Cancer Patients. Clin Cancer Res 31:P1\u20137","journal-title":"Clin Cancer Res"},{"key":"8070_CR35","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A et al (2024) Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol Off J Am Soc Clin Oncol 42:1738\u20131744","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"8070_CR36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s12094-018-1915-3","volume":"21","author":"Abdel-Rahman","year":"2019","unstructured":"Abdel-Rahman (2019) Outcomes of early-stage breast cancer patients treated with sequential anthracyclines-taxanes in relationship to relative dosing intensity: a secondary analysis of a randomized controlled trial. Clin Transl Oncol 21(2):239\u2013249","journal-title":"Clin Transl Oncol"},{"key":"8070_CR37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12885-018-4365-y","volume":"18","author":"S Liutkauskiene","year":"2018","unstructured":"Liutkauskiene S et al (2018) Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes. BMC Cancer 18:453","journal-title":"BMC Cancer"},{"key":"8070_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10549-017-4646-1","volume":"169","author":"L Zhang","year":"2018","unstructured":"Zhang L et al (2018) Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+\/PR+, HER2- vs. triple-negative. Breast Cancer Res Treat 169:175\u2013187","journal-title":"Breast Cancer Res Treat"},{"key":"8070_CR39","doi-asserted-by":"publisher","first-page":"13241","DOI":"10.1038\/s41598-020-70187-8","volume":"10","author":"W Qi","year":"2020","unstructured":"Qi W et al (2020) The effect of reduced RDI of chemotherapy on the outcome of breast cancer patients. Sci Rep 10:13241","journal-title":"Sci Rep"},{"key":"8070_CR40","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","volume":"33","author":"SJ Isakoff","year":"2015","unstructured":"Isakoff SJ et al (2015) TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 33:1902\u20131909","journal-title":"J Clin Oncol"},{"key":"8070_CR41","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108\u20132121","journal-title":"N Engl J Med"},{"key":"8070_CR42","doi-asserted-by":"publisher","first-page":"S1289","DOI":"10.1016\/j.annonc.2021.08.2089","volume":"32","author":"J Cort\u00e9s","year":"2021","unstructured":"Cort\u00e9s J et al (2021) LBA16 KEYNOTE-355: final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. Ann Oncol 32:S1289\u2013S1290","journal-title":"Ann Oncol"},{"key":"8070_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(21)00019-X","volume":"22","author":"E Amir","year":"2021","unstructured":"Amir E, Cescon DW (2021) Pembrolizumab monotherapy in metastatic triple-negative breast cancer. Lancet Oncol 22:415\u2013417","journal-title":"Lancet Oncol"},{"key":"8070_CR44","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.2021.39.15_suppl.1007","volume":"39","author":"L Chen","year":"2021","unstructured":"Chen L et al (2021) Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): a prospective, single-arm, phase 2 study. J Clin Oncol 39:1007\u20131007","journal-title":"J Clin Oncol"},{"key":"8070_CR45","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS et al (2023) Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet Lond Engl 402:1423\u20131433","journal-title":"Lancet Lond Engl"},{"key":"8070_CR46","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/gutjnl-2019-319970","volume":"70","author":"J Gout","year":"2021","unstructured":"Gout J et al (2021) Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut 70:743\u2013760","journal-title":"Gut"},{"key":"8070_CR47","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM et al (2019) Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 51:202\u2013206","journal-title":"Nat Genet"},{"key":"8070_CR48","doi-asserted-by":"publisher","first-page":"117305","DOI":"10.1016\/j.ejmech.2025.117305","volume":"286","author":"T Li","year":"2025","unstructured":"Li T et al (2025) Exploiting synthetic lethality in PDAC with antibody drug conjugates and ATR inhibition. Eur J Med Chem 286:117305","journal-title":"Eur J Med Chem"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08070-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08070-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08070-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:54:25Z","timestamp":1790312065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08070-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["8070"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08070-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University (SYSKY-2025-006-01) provided ethical approval for this study. Patients gave their written informed consent for the future use of their samples and clinical data. For deceased patients, a waiver has been granted. This study complies with the Good Clinical Practice (GCP) guidelines for drug trials, the Interim Measures for the Administration of Investigator-Initiated Clinical Research by Medical and Health Institutions, and the Declaration of Helsinki. Clinical and personal data collected from study participants will be used exclusively for scientific research purposes, involving patient privacy considerations. The collected patient data will be managed uniformly to prevent any leakage of personal privacy.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Institutional Review Board of Sun Yat-sen Memorial Hospital, Sun Yat-sen University. Because the study involved only the analysis of existing de-identified data, the requirement for obtaining informed consent from participa nts was waived.","order":2,"name":"Ethics","label":"Inform consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"10"}}